A Phase 1 interventional study of HLX208 and HLX208 in NSCLC, sponsored by Shanghai Henlius Biotech. Completed at 1 site in China. Open to participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-04-05.
Sponsored by Shanghai Henlius Biotech (part of Fosun Pharma) · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
This study is divided into Part I and Part II. Part I is the food effect study. A total of 20 healthy subjects, regardless of gender, will be enrolled in a randomized, open-label, crossover design.
Part II is the drug-drug interaction study, an open-label and sequential design. 32 healthy subjects are planned to be enrolled and divided into group A and group B. Group A is to evaluate the influence of itraconazole as CYP3A4 strong inhibitory on HLX208. Group B was to evaluate the effect of rifampicin as a strong inducer of CYP3A4 on HLX208.
Shanghai Henlius Biotech is the lead sponsor of 132 studies on the registry; 56 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HLX208 900mg in the fast state
Drug: HLX208
HLX208 900mg in the fed state
Drug: HLX208
HLX208 + Itraconazole group
Drug: HLX208 · Drug: Itraconazole 200 mg
HLX208 + rifampicin group
Drug: HLX208 · Drug: Rifampicin
Subjects will receive treatment HLX208 900 mg in the fast state followed by 7 days washout ,then receive treatment HLX208 900 mg in the fed state
Subjects will receive treatment HLX208 900 mg in the fed state followed by 7 days washout ,then receive treatment HLX208 900 mg in the fast state.
450 mg
900 mg
200 mg
600mg
Pharmacokinetics parameter Cmax of HLX208
Cmax of HLX208
Time frame: up to 48 hours
Pharmacokinetics parameter AUC0-t of HLX208
AUC0-t of HLX208
Time frame: up to 48 hours
Pharmacokinetics parameter AUC0-inf of HLX208
AUC0-inf of HLX208
Time frame: up to 48 hours
other pharmacokinetics parameter Tmax of HLX208
Tmax of HLX208
Time frame: up to 48 hours
other pharmacokinetics parameter Tlag of HLX208
Tlag of HLX208
Time frame: up to 48 hours
other pharmacokinetics parameter t1/2 of HLX208
t1/2 of HLX208
Time frame: up to 48 hours
other pharmacokinetics parameter CL/F of HLX208
CL/F of HLX208
Time frame: up to 48 hours
other pharmacokinetics parameter Vd/F of HLX208
Vd/F of HLX208
Time frame: up to 48 hours
other pharmacokinetics parameter MRT of HLX208
MRT of HLX208
Time frame: up to 48 hours
other pharmacokinetics parameter %AUCex of HLX208
%AUCex of HLX208
Time frame: up to 48 hours
The incidence and severity of adverse events/serious adverse events
Occurrence of Serious Adverse Event (SAE), Adverse Event (AE)
Time frame: up to 17 days after the last dose
Plan to share: No
No publications or documents are linked to this record.
Ran from Jul 2023 to primary completion in Dec 2023, 5 months.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: BRAF V600E Inhibitor HLX208